RAPT Therapeutics (RAPT) Equity Average: 2020-2024
Historic Equity Average for Therapeutics (RAPT) over the last 5 years, with Sep 2024 value amounting to $102.4 million.
- Therapeutics' Equity Average fell 45.04% to $102.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $102.4 million, marking a year-over-year decrease of 45.04%. This contributed to the annual value of $196.1 million for FY2023, which is 9.12% down from last year.
- Latest data reveals that Therapeutics reported Equity Average of $102.4 million as of Q3 2024, which was down 14.72% from $120.0 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Equity Average ranged from a high of $232.8 million in Q1 2023 and a low of $97.9 million during Q1 2021.
- Over the past 3 years, Therapeutics' median Equity Average value was $185.0 million (recorded in 2022), while the average stood at $175.0 million.
- Per our database at Business Quant, Therapeutics' Equity Average surged by 81.24% in 2021 and then crashed by 45.04% in 2024.
- Therapeutics' Equity Average (Quarterly) stood at $107.1 million in 2020, then surged by 81.24% to $194.1 million in 2021, then climbed by 11.90% to $217.2 million in 2022, then fell by 26.39% to $159.9 million in 2023, then tumbled by 45.04% to $102.4 million in 2024.
- Its Equity Average stands at $102.4 million for Q3 2024, versus $120.0 million for Q2 2024 and $138.9 million for Q1 2024.